U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H37N3O3S3
Molecular Weight 559.807
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLOBALAGLIATIN

SMILES

O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6

InChI

InChIKey=QIIVJLHCZUTGSD-CUBQBAPOSA-N
InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H37N3O3S3
Molecular Weight 559.807
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27163171

LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM. Eli Lilly is developing LY 2608204 as an orally administered, once-daily therapy for type 2 diabetes. LY-2608204 is in phase I clinical trials for the treatment of type 2 diabetes.

Originator

Curator's Comment: # Eli Lilly

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35557
Gene ID: 2645.0
Gene Symbol: GCK
Target Organism: Homo sapiens (Human)
42.0 nM [EC50]
42.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
29.36 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
69.43 ng/mL
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.88 ng/mL
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
342 ng/mL
240 mg 1 times / day steady-state, oral
dose: 240 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
471.5 ng/mL
320 mg 1 times / day steady-state, oral
dose: 320 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
369.71 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1009.35 ng × h/mL
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3036.75 ng × h/mL
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6028.2 ng × h/mL
240 mg 1 times / day steady-state, oral
dose: 240 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9218.38 ng × h/mL
320 mg 1 times / day steady-state, oral
dose: 320 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Generation of stem cell-derived β-cells from patients with type 1 diabetes.
2016 May 10
Patents

Sample Use Guides

Oral capsules of LY2608204 given once daily at a starting dose of 160mg, which may be titrated in 3 dose escalations to 240mg, 320mg and 400mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
Route of Administration: Oral
Treatment with 1uM of LY2608204 increases insulin release in T1D and ND SC-β cell lines at both low- and high-glucose challenges compared with control by a factor of 2.0 on average.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:50:55 UTC 2023
Edited
by admin
on Sat Dec 16 05:50:55 UTC 2023
Record UNII
5A0L003HEY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLOBALAGLIATIN
Common Name English
SY-004
Code English
(1R,2S)-2-CYCLOHEXYL-1-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(5-((2-(1-PYRROLIDINYL)ETHYL)THIO)-2-THIAZOLYL)CYCLOPROPANECARBOXAMIDE
Systematic Name English
LY-2608204
Common Name English
Globalagliatin [WHO-DD]
Common Name English
LY2608204
Code English
Code System Code Type Description
FDA UNII
5A0L003HEY
Created by admin on Sat Dec 16 05:50:55 UTC 2023 , Edited by admin on Sat Dec 16 05:50:55 UTC 2023
PRIMARY
CAS
1234703-40-2
Created by admin on Sat Dec 16 05:50:55 UTC 2023 , Edited by admin on Sat Dec 16 05:50:55 UTC 2023
PRIMARY
SMS_ID
300000041385
Created by admin on Sat Dec 16 05:50:55 UTC 2023 , Edited by admin on Sat Dec 16 05:50:55 UTC 2023
PRIMARY
DRUG BANK
DB12284
Created by admin on Sat Dec 16 05:50:55 UTC 2023 , Edited by admin on Sat Dec 16 05:50:55 UTC 2023
PRIMARY
PUBCHEM
46832368
Created by admin on Sat Dec 16 05:50:55 UTC 2023 , Edited by admin on Sat Dec 16 05:50:55 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> ACTIVATOR
ALLOSTERIC INHIBITOR
EC50
Related Record Type Details
ACTIVE MOIETY